Tectonic Therapeutic Inc. (TECX)
| Bid | 19.6 |
| Market Cap | 367.28M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -49.57M |
| EPS (ttm) | -6.83 |
| PE Ratio (ttm) | -2.88 |
| Forward PE | -3.54 |
| Analyst | Buy |
| Ask | 20.6 |
| Volume | 139,618 |
| Avg. Volume (20D) | 265,311 |
| Open | 20.97 |
| Previous Close | 20.86 |
| Day's Range | 19.66 - 20.88 |
| 52-Week Range | 1.40 - 61.07 |
| Beta | 1.64 |
About TECX
Tectonic Therapeutic, Inc., a clinical stage biotechnology company focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G-protein coupled receptors(GPCRs). It offers GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's pipeline products include RXFP1 agonist, which is in ongoing phase 1a and 1b for the indication of heart failure...
Analyst Forecast
According to 6 analyst ratings, the average rating for TECX stock is "Buy." The 12-month stock price forecast is $67, which is an increase of 240.45% from the latest price.
Stock Forecasts
2 months ago · seekingalpha.com
Tectonic: Expansion Of TX45 Candidate Possible After Positive Interim DataPositive interim results released from phase 1b study, using TX45 for the treatment of patients with pulmonary hypertension heart failure with preserved ejection fraction. Data from phase 1b study usi...